AGRF (Australian Genome Research Facility Ltd) and Integrated Sciences are excited to announce a new partnership that will bring advanced genomics capabilities to researchers across Australia and New Zealand. This collaboration will enable AGRF’s Advanced Genomics group to offer cutting-edge epigenetic services utilising EpiCypher’s CUT&RUN and CUT&Tag technologies.
Read MoreAGRF Expands Olink® Platform with Signature Q100, Boosting Biomarker Discovery and Prognosis Capabilities
/
Media Release
AGRF is thrilled to announce the expansion of its Olink® fleet with the addition of the Olink Signature Q100. Funded by The Kids Research Institute (The Kids) in Perth, the platform joins our certified Olink Explore HT and Explore 3072 workflows and will allow us to run the Olink Target 96 and 48 workflows, enabling researchers with both absolute and relative quantitative proteomic data, driving the identification and validation of biomarkers from early discovery to implementation and disease risk prediction.
Read MoreAGRF achieves Olink® Certified Service Provider Status
/
AGRF are proud to announce its recent recognition as an Olink® Certified Service Provider.
Read MoreMilestone Achievement For Paediatric Cancer Research
/
In an exciting step forward for children’s cancer research, the Australian Cancer Research Foundation (ACRF) has awarded a $2 million grant to Children’s Cancer Institute. The grant will advance the initiation of their Spatial Immune-oncology Research program, aiming to unlock the potential of immunotherapies specifically tailored for childhood cancer. A key partnership with AGRF will introduce our Olink technology for in-depth protein analysis, unlocking new possibilities in paediatric cancer research.
Read MoreAGRF: Bringing Olink® Next Generation Proteomic Technology to Australia.
/
AGRF is thrilled to announce the introduction of the Olink Explore high throughput platform to our fleet of cutting-edge technologies, bringing the most advanced proteomic technology to Australia and positioning AGRF as a truly multi-omics destination. This strategic move promises to be a game changer in precision medicine, offering researchers a full multi-omics profile of patient and biobank samples.
Read More